News | August 02, 2022
Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes
The two generic drugs have been launched under the brand names Jankey & Sitenali.
The two generic drugs have been launched under the brand names Jankey & Sitenali.
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
In clinical trials, treatment proved more effective than other therapies evaluated
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Subscribe To Our Newsletter & Stay Updated
